Buyout firm GTCR is weighing a bid for Hellman & Friedman’s residential security company SimpliSafe, sources say https://t.co/XHrZ8aPdgG ...

Private equity firm GTCR is in talks with direct lenders including KKR to drum up financing to support a bid to acquire generic drugmaker Zentiva, according to sources https://t.co/rZb0Xmdi2r ...

GTCR is in talks to acquire prepaid gift-card provider Blackhawk Network https://t.co/mrO0eItJUP ...

Core Insights - GTCR, a Chicago-based private equity firm, achieved a significant exit by selling Worldpay for $24.25 billion, marking the largest private equity exit of 2025 so far [2][3] - The firm has managed to navigate a challenging market environment, completing notable transactions while many in the industry struggle to find buyers for their businesses [4][5] Group 1: Company Performance - GTCR manages $45 billion in assets, which is relatively small compared to major players like Blackstone and KKR, yet it has executed a remarkable transaction [3] - The firm sold Worldpay less than two years after acquiring a 55% stake from FIS for $18.5 billion, effectively doubling its investment [3] - GTCR is expected to return over $5 billion to investors this year, continuing a strong performance record for its flagship funds [4][5] Group 2: Historical Context and Leadership - Founded in 1980, GTCR has a long history in the private equity sector, with its founders being pioneers in the industry [5] - The current co-CEOs, Collin Roche and Dean Mihas, represent the second generation of leadership, with Roche having joined in 1996 and Mihas in 2001 [6] Group 3: Recent Transactions - Prior to the Worldpay sale, GTCR sold AssuredPartners for $13.45 billion and has also divested smaller companies like Antylia Scientific and Itel for over $1 billion each [4][5] - The Worldpay deal involved a complex asset swap with Global Payments, which acquired Worldpay while selling its card issuing solutions to FIS for $13.5 billion [7] Group 4: Future Strategy - GTCR is focusing on identifying new acquisition opportunities, having raised a new flagship fund of $11.5 billion and a strategic growth fund of $3.6 billion [8] - The firm currently has over $10 billion available for deployment, indicating a strong position to capitalize on market uncertainties [8]

Core Insights - Resonetics has acquired the nitinol gun drilling operations and related assets from Medical Component Specialists (MCS) to enhance its U.S.-based nitinol strategy and strengthen supply chain resilience [1][3] - The acquisition is part of Resonetics' initiative to improve material availability and reduce lead times for customers, which is critical for the production of high-performance nitinol tubing [3][2] - This investment builds on previous expansions in nitinol tubing capabilities, ensuring precision and control for rapid prototyping and scalable manufacturing of complex medical implants [3][4] Company Overview - Resonetics, founded in 1987, specializes in advanced engineering and manufacturing solutions for the medical device industry, focusing on laser processing, nitinol manufacturing, and photochemical machining [4] - The company operates 17 facilities with over 3,000 associates across multiple countries, including the U.S., Canada, and Switzerland, and is backed by private equity firms Carlyle and GTCR [4] - Resonetics is committed to being an open-source supplier to medical device OEMs and contract manufacturers, emphasizing quality, responsiveness, and innovation [4]

In a major move to strengthen its position in the global health and well-being sector, TELUS Corporation (TU) has partnered with GTCR, a prominent private equity firm with deep expertise in healthcare, to support TELUS Health’s acquisition of Workplace Options.This acquisition, valued at approximately C$500 million ($350 million) in cash, excluding about C$100 million ($70 million) in assumed debt, marks a pivotal step in TELUS Health’s journey to become a global leader in digital-first wellness solutions. ...

Core Insights - TELUS Corporation announced a strategic partnership with GTCR to support the acquisition of Workplace Options for approximately $500 million (US$350 million), net of assumed debt of about $100 million (US$70 million) [1][2] - The acquisition aims to enhance TELUS Health's position in the global wellbeing solutions market, providing services to over 150 million lives across more than 200 countries [1][5] - GTCR will invest US$200 million as part of the acquisition, leveraging its extensive healthcare investment expertise to accelerate TELUS Health's growth [1][4] Company Overview - TELUS Health is focused on becoming the most trusted wellbeing company globally, integrating advanced healthcare technology with employee support services [7] - The company provides a holistic approach to health and wellbeing, including Employee and Family Assistance Programs (EFAPs), mental health resources, and workplace wellness initiatives [7] - TELUS Health's digital health platforms empower healthcare professionals and organizations to deliver personalized care efficiently [7] Strategic Benefits - The partnership with Workplace Options will create a standardized model for delivering robust EFAP and wellbeing services, enhancing customer experience and global reach [5] - The combination of TELUS' infrastructure and Workplace Options' digital capabilities, along with TELUS Digital's AI expertise, provides a competitive advantage in the market [5] - The collaboration is expected to unlock significant growth opportunities and new revenue streams for TELUS Health [2][4]

Core Viewpoint - The Federal Trade Commission (FTC) is opposing GTCR's acquisition of Surmodics for $627 million, citing concerns over reduced competition in the hydrophilic coating market, which could lead to higher prices and lower quality of products and services [5][6][26]. Group 1: Acquisition Opposition - GTCR's proposed acquisition price of $43 per share represents a 41% premium over Surmodics' recent trading average [2]. - The FTC has delayed the transaction and filed a lawsuit, highlighting that GTCR's previous acquisition of Biocoat has already concentrated market power in the hydrophilic coating sector [4][5]. - The FTC argues that the merger would give the combined entity over 50% market share, significantly diminishing competition and innovation in the industry [5][26]. Group 2: Surmodics Overview - Surmodics, established in 1979 and publicly listed since 1998, specializes in medical device coating technologies and develops vascular intervention devices and in vitro diagnostic technologies [7]. - The company holds a leading position in coating technology, with its team producing over 40 patents annually [8]. - Surmodics' product offerings include medical device coatings, interventional products, and in vitro diagnostics, with notable innovations like the Preside™ hydrophilic coating platform [12][19]. Group 3: Financial Performance - Surmodics reported an 18% year-over-year increase in total revenue for Q2 2024, with adjusted EBITDA rising by $6.3 million [20]. - The in vitro diagnostics segment saw a 5% revenue decline to $7.1 million, while the medical device segment grew by 40% to $3.2 million, driven by vascular intervention products [21]. - Revenue from medical device coating royalties and licensing fees increased by 27% to $2.2 million [23]. Group 4: Market Position - The FTC has identified Surmodics and Biocoat as the first and second largest players in the hydrophilic coating market, collectively holding over 50% market share [25]. - The FTC's concerns reflect a broader trend of private equity firms potentially stifling competition and innovation in the healthcare sector, which could lead to increased medical costs for consumers [26].

大会进行时：首届全球骨科大会 | 参会须知 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 FTC随后推迟该笔交易，并提起诉讼，在相关文件中，FTC描述： 2025年4月17日-18日，美国伊利诺伊州、明尼苏达州宣布加入联邦贸易委员会（ FTC），共同反对 GTCR公司以 6.27亿美元（合约45亿人民币） 收购亲水涂层公司 Surmodics，此前2024年5月， Surmodics接受了GTCR的收购要约，FTC随后推迟该笔交易，并于2025年3月份提起诉讼。 # 收购遭反对 2024年3月，GTCR预计以每股43美元的价格收购Surmodics，这一价格较Surmodics近30天成交量加权 平均收盘价溢价约 41% 。 "2022年底，GTCR公司收购了美国第二大亲水涂层供应商Biocoat的多数股权。" "目前，GTCR计划收购美国最大的亲水涂层供应商Surmodics。 若此次收购完成，合并后的公司将控制超过 50%的外包亲水涂层市场份额。 因此，此次收购可能导致本已集中的市场竞争大幅减弱，直接竞争关系消 失，进而引发产品质量和服务水平下降、创新能力降低，以及亲水 ...

Core Insights - Surmodics, Inc. (SRDX) reported a strong performance in the last quarter, with a loss per share that was 51.9% narrower than market estimates and sales exceeding estimates by 8.3%, driven by solid prospects in the thrombectomy business [1][3] - The company is likely to be acquired by GTCR for an estimated total equity valuation of $627 million, with the deal expected to close by the end of March, potentially offering double-digit returns for investors [2][5] - Surmodics has a market capitalization of $404.58 million and projects a remarkable 162.5% growth for fiscal 2025, maintaining a strong performance trajectory [3] Acquisition Details - Surmodics entered into a definitive agreement in May 2024 to be acquired by GTCR, with shareholders set to receive $43.00 per share in cash [5] - The acquisition faces challenges as the FTC has blocked the deal due to anti-competitive concerns, prompting Surmodics to consider legal action against the FTC [5][11] Financial Performance - Surmodics demonstrated solid improvement in both top and bottom lines for Q1 of fiscal 2025, with notable increases in performance coatings royalty revenues and sales from the Pounce thrombectomy device platforms [8] - The gross margin expansion is a positive indicator for the stock, despite some segmental sales declines attributed to unfavorable order timing [10] Thrombectomy Business Prospects - The company aims to leverage its proprietary Pounce thrombectomy platform technology, with early results from a study presented at the TCT Symposium and FDA clearance for the Pounce XL Thrombectomy System [7] - Limited market evaluations of the product are expected to generate additional revenues during fiscal 2025 [7] Estimate Trends - Surmodics is experiencing a positive estimate revision trend for fiscal 2025, with the Zacks Consensus Estimate for earnings per share improving by 1 cent to 19 cents [13] - The consensus estimate for Q2 fiscal 2025 revenues is projected at $33 million, indicating a 3.3% increase from the previous year [13]